BC Extra | Sep 16, 2019
Company News

Sept. 16 Company Quick Takes: FDA accepts Seattle Genetics' BLA; plus Akynzeo, Purdue, Amplyx, Abbott-Sanofi

FDA to review enfortumab vedotin  Seattle Genetics Inc. (NASDAQ:SGEN) and partner Astellas Pharma Inc. (JASDAQ:4503) said FDA has accepted a BLA and granted Priority Review to enfortumab vedotin for locally advanced or metastatic urothelial cancer....
BC Extra | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

GSK acquires celiac company Sitari  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is acquiring Sitari Pharmaceuticals Inc. (La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon Ventures and the pharma. Financial...
BC Extra | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program  Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....
BC Extra | Jul 2, 2019
Company News

Management tracks: Purdue hires CSO; plus Intra-Cellular, Dementia Discovery Fund and Oasmia

Purdue Pharma L.P. (Stamford, Conn.) hired Julie Ducharme as VP and CSO. She was managing director and head of R&D at Mundipharma Research Ltd. (Cambridge, U.K.). CNS disease company Intra-Cellular Therapies Inc. (NASDAQ:ITCI) hired Karen...
BC Extra | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

Atara Biotherapeutics Inc. (NASDAQ:ATRA) hired Pascal Touchon as president and CEO, effective June 24. He was global head cell & gene at Novartis AG (NYSE:NVS; SIX:NOVN), where he was responsible for the global launch of...
BC Extra | May 2, 2019
Company News

May 2 Company Quick Takes: Agios, Celgene/Presage, Purdue, Amgen/Syapse

Label expansion in AML for Agios’ Tibsovo  FDA approved an sNDA for Tibsovo ivosidenib from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) as monotherapy for adults with newly diagnosed acute myelogenous leukemia (AML) with a susceptible isocitrate dehydrogenase...
BC Extra | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said EVP and Chief Medical and Development Officer Adam Steensberg will become interim CEO on March 1. He will succeed Britt Meelby Jensen, who is leaving the company on Feb....
BC Week In Review | Jan 11, 2019
Company News

Purdue, Ocular partner to develop non-opioid therapies

Purdue Pharma L.P. (Stamford, Conn.) and Ocular Therapeutix Inc. (NASDAQ:OCUL) will partner to develop and commercialize Purdue's non-opioid new chemical entities with Ocular's bioresorbable hydrogel-based technology. Ocular is responsible for discovery and bringing a product...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Dec 21, 2018
Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Dec. 14, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The...
Items per page:
1 - 10 of 319
BC Extra | Sep 16, 2019
Company News

Sept. 16 Company Quick Takes: FDA accepts Seattle Genetics' BLA; plus Akynzeo, Purdue, Amplyx, Abbott-Sanofi

FDA to review enfortumab vedotin  Seattle Genetics Inc. (NASDAQ:SGEN) and partner Astellas Pharma Inc. (JASDAQ:4503) said FDA has accepted a BLA and granted Priority Review to enfortumab vedotin for locally advanced or metastatic urothelial cancer....
BC Extra | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

GSK acquires celiac company Sitari  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is acquiring Sitari Pharmaceuticals Inc. (La Jolla, Calif.), the first company formed and funded under a 2013 build-to-buy partnership between Avalon Ventures and the pharma. Financial...
BC Extra | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program  Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....
BC Extra | Jul 2, 2019
Company News

Management tracks: Purdue hires CSO; plus Intra-Cellular, Dementia Discovery Fund and Oasmia

Purdue Pharma L.P. (Stamford, Conn.) hired Julie Ducharme as VP and CSO. She was managing director and head of R&D at Mundipharma Research Ltd. (Cambridge, U.K.). CNS disease company Intra-Cellular Therapies Inc. (NASDAQ:ITCI) hired Karen...
BC Extra | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

Atara Biotherapeutics Inc. (NASDAQ:ATRA) hired Pascal Touchon as president and CEO, effective June 24. He was global head cell & gene at Novartis AG (NYSE:NVS; SIX:NOVN), where he was responsible for the global launch of...
BC Extra | May 2, 2019
Company News

May 2 Company Quick Takes: Agios, Celgene/Presage, Purdue, Amgen/Syapse

Label expansion in AML for Agios’ Tibsovo  FDA approved an sNDA for Tibsovo ivosidenib from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) as monotherapy for adults with newly diagnosed acute myelogenous leukemia (AML) with a susceptible isocitrate dehydrogenase...
BC Extra | Jan 25, 2019
Company News

Management Tracks: Zealand, BeiGene

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said EVP and Chief Medical and Development Officer Adam Steensberg will become interim CEO on March 1. He will succeed Britt Meelby Jensen, who is leaving the company on Feb....
BC Week In Review | Jan 11, 2019
Company News

Purdue, Ocular partner to develop non-opioid therapies

Purdue Pharma L.P. (Stamford, Conn.) and Ocular Therapeutix Inc. (NASDAQ:OCUL) will partner to develop and commercialize Purdue's non-opioid new chemical entities with Ocular's bioresorbable hydrogel-based technology. Ocular is responsible for discovery and bringing a product...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Dec 21, 2018
Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Dec. 14, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The...
Items per page:
1 - 10 of 319